铁螯合治疗MDS的血液学改善:来自“Rete Ematologica Lombarda” 的经验

Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the “Rete Ematologica Lombarda”
2014-01-02 13:57点击:1208次发表评论
期刊: LEUKEMIA RES2013年10月10期37卷

 

To analyze the unpredicted event of hematological improvement (HI) during iron-chelation therapy (ICT), we reviewed a series of 53 myelodysplastic patients with transfusion dependency in a retrospective study involving 8 centers afferent to the “Rete Ematologica Lombarda”. According to the IWG response criteria published in the year 2000, we observed erythroid responses in 19 patients (35.1%), 5 major (9.2%) and 14 minor (25.9%). In the assessable patients, platelet response was 8/13 (61%) and neutrophil response was 13/17 (76.4%). Only in patients with erythroid improvement, multilineage responses were observed. Apparently, patients with greater erythropoiesis dysfunction may take more advantage.

 

主要结论:对于红细胞生成异常更严重的患者,接受地拉罗司和去铁胺治疗的获益更大。

 

学科代码:肿瘤学 血液病学   关键词:铁螯合治疗MDS的血液学改善 ,全球精选文摘 爱思唯尔医学网, Elseviermed
来源: 爱思唯尔
爱思唯尔介绍:全球最大的科技医学出版商――爱思唯尔以出版发行高品质的、前沿的科学、技术和医学信息,并保证其满足全世界科技和医学工作者对于信息的需求而著称。现在,公司建立起全球的学术体系,拥有7,000名期刊编辑、70,000名编辑委员会成员、200,000专家审稿人以及500,000名作者,每年出版2,000本期刊和2,200种新书,并拥有17,000种在库图书。 马上访问爱思唯尔网站http://www.elseviermed.cn
顶一下(0
您可能感兴趣的文章
    发表评论网友评论(0)
      发表评论
      登录后方可发表评论,点击此处登录